Press Release

Endocrine Society Recommends Universal Diabetes Testing at First Prenatal Visit

January 14, 2014

Society responds to USPSTF statement on gestational diabetes screening

Chevy Chase, MD—The Endocrine Society is encouraged by the U.S. Preventive Services Task Force’s (USPSTF) efforts to promote gestational diabetes screening and recommends going a step further to identify undiagnosed type 2 diabetes cases before harmful pregnancy complications can develop.

The USPSTF recommendations released Monday called for pregnant women to be tested for gestational diabetes after 24 weeks gestation.

The Society agrees that pregnant women who have not previously been diagnosed with overt or gestational diabetes should be tested at this stage of pregnancy. However, the Society also recommends universal diabetes testing for women at the first prenatal visit in its Diabetes and Pregnancy Clinical Practice Guideline published in the November 2013 issue of the Society’s Journal of Clinical Endocrinology and Metabolism. The test should be done before 13 weeks’ gestation or as soon as possible thereafter.

“Given that many cases of type 2 diabetes are undiagnosed, it’s important to ascertain early in pregnancy whether women have this condition,” said Ian Blumer, MD, of the Charles H. Best Diabetes Centre in Whitby, Ontario, Canada, and chair of the task force that authored the guideline. “Untreated diabetes poses serious risks to the mother and the fetus, so it is important to reduce the chance of complications through early diagnosis and treatment.”

As many as one in five women may develop gestational diabetes – a form of diabetes that has its onset during pregnancy. However, traditional testing strategies only identify about 25 percent of the cases. Women who go undiagnosed are at an increased risk of having an overly large baby, which can complicate delivery.

When pregnant women are screened for gestational diabetes at 24 to 28 weeks gestation, the Endocrine Society recommends using a one-step testing approach in line with the consensus panel of the International Association of the Diabetes and Pregnancy Study Groups’ protocol. This involves pregnant women taking a 75-g oral glucose tolerance test, which is more sensitive and can help physicians diagnose more cases. This differs from the 50-g oral glucose challenge test, which is commonly used in the United States. As the USPSTF noted in its statement, many pregnant women receive this test and are only given the oral glucose tolerance test if the first test yields abnormal results.

“The Society’s task force felt the overriding concern of pregnant women was to avoid complications that can harm the fetus,” Blumer said. “Using the more sensitive, one-step test supports the goal of early diagnosis and treatment.”

Other members of the Endocrine Society task force that developed the Diabetes and Pregnancy Clinical Practice Guideline include: Eran Hadar of Helen Schneider Hospital for Women in Petach Tikva, Israel; David R. Hadden of Royal Victoria Hospital in Belfast, Northern Ireland; Lois J. Jovanovič of Sansum Diabetes Research Institute in Santa Barbara, CA; Jorge H. Mestman of the University of Southern California in Los Angeles; M. Hassan Murad of the Mayo Clinic in Rochester, MN; and Yariv Yogev of Helen Schneider Hospital for Women.

The Society established the Clinical Practice Guideline (CPG) Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis and treatment of endocrine-related conditions. Each CPG is created by a task force of topic-related experts in the field. Task forces rely on scientific reviews of the literature in the development of CPG recommendations. The Endocrine Society does not solicit or accept corporate support for its CPGs. All CPGs are supported entirely by Society funds.

About Endocrine Society

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses, and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at Follow us on X (formerly Twitter) at @TheEndoSociety and @EndoMedia.

Media Contacts

Colleen Williams Senior Communications Manager, Public Relations Phone: (202)-971-3611 [email protected]

Jenni Glenn Gingery Director, Communications and Media Relations Phone: (202)-971-3655 [email protected]

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.